NeoGenomics (NASDAQ:NEO) Stock Rating Upgraded by BidaskClub

NeoGenomics (NASDAQ:NEO) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports.

A number of other brokerages have also recently issued reports on NEO. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective (down from $15.00) on shares of Nabriva Therapeutics in a report on Wednesday, May 1st. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. NeoGenomics currently has an average rating of “Buy” and a consensus target price of $21.11.

NASDAQ:NEO opened at $23.85 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market capitalization of $2.28 billion, a PE ratio of 149.06 and a beta of 0.78. The business has a fifty day moving average of $22.80. NeoGenomics has a 12 month low of $11.05 and a 12 month high of $24.84.



NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, April 30th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $89.71 million. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. The business’s quarterly revenue was up 50.8% on a year-over-year basis. During the same period last year, the company posted $0.04 earnings per share. On average, research analysts forecast that NeoGenomics will post 0.18 EPS for the current year.

In related news, insider William Bonello sold 7,200 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $23.53, for a total transaction of $169,416.00. Following the transaction, the insider now directly owns 13,935 shares in the company, valued at $327,890.55. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Raymond R. Hipp sold 150,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $22.41, for a total transaction of $3,361,500.00. Following the transaction, the director now owns 256,059 shares in the company, valued at $5,738,282.19. The disclosure for this sale can be found here. Insiders have sold 338,876 shares of company stock valued at $7,674,362 over the last quarter. Corporate insiders own 8.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its holdings in NeoGenomics by 3.8% during the second quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock worth $562,000 after purchasing an additional 945 shares during the last quarter. Summit Creek Advisors LLC boosted its holdings in NeoGenomics by 0.3% during the second quarter. Summit Creek Advisors LLC now owns 348,208 shares of the medical research company’s stock worth $7,640,000 after purchasing an additional 960 shares during the last quarter. Suntrust Banks Inc. boosted its holdings in NeoGenomics by 2.6% during the fourth quarter. Suntrust Banks Inc. now owns 39,959 shares of the medical research company’s stock worth $504,000 after purchasing an additional 1,028 shares during the last quarter. Legal & General Group Plc boosted its holdings in NeoGenomics by 13.3% during the fourth quarter. Legal & General Group Plc now owns 11,964 shares of the medical research company’s stock worth $151,000 after purchasing an additional 1,405 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its holdings in NeoGenomics by 200.0% during the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 84.10% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Recommended Story: How to build a Fibonacci channel

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.